16 completed, 4 terminated, 3 recruiting, 1 unknown. 24 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 24 | Completed 16, Terminated 4, Recruiting 3, Unknown 1 |
Follow Phobia, Social: new trials by email Literature Review of Phobia, Social trials Research Report on Phobia, Social
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Caplyta Versus Placebo for Adults With Social Anxiety Disorder Lumateperone 42 mg, Placebo - Social Anxiety Disorder (SAD) | Phase 4 | Recruiting | Jason Careri | 40 | 2026-09-10 | 2026-09-15 |
| Investigating the Effects of Cannabidiol on Social Anxiety Disorder Cannabidiol, Placebo - Phobia, Social | Phase 4 | Recruiting | Massachusetts Institute of Technology | 50 | 2025-07-10 | 2026-08-11 |
| Comparison of the Effectiveness Level of Virtual Reality Exposure Therapy With Sertraline Treatment in Social Anxiety Disorder Virtual Reality Exposure Therapy, Sertraline (Oral Antidepressant) - Social Anxiety Disorder | Phase 4 | Recruiting | Emine Kanmaz | 56 | 2024-11-15 | 2025-09-25 |
| Cariprazine Versus Placebo for Social Anxiety Disorder Cariprazine, Placebo - Social Anxiety Disorder | Phase 4 | Completed | The Medical Research Network | 40 | 2022-07-18 | 2024-08-21 |
| A 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity Methylphenidate Hydrochloride Controlled-Release Capsules, Placebo Capsule - Attention Deficit Hyperactivity Disorder, Generalized Anxiety Disorder | Phase 4 | Completed | McMaster University | 60 | 2019-04-20 | 2023-10-26 |
| Treatments for Anxiety: Meditation and Escitalopram Mindfulness-Based Stress Reduction, Escitalopram - Anxiety Disorders, Generalized Anxiety Disorder | Phase 4 | Completed | Georgetown University | 276 | 2018-06-18 | 2022-01-11 |
| A Study of the Efficacy of Botox in the Treatment of Social Anxiety Disorder botulinum toxin A, Placebo - Anxiety Disorder Social, Anxiety | Phase 4 | Terminated | Daniel Lieberman | 4 | 2017-02-01 | 2019-01-23 |
| Brief Intervention to Reduce Fear of Public Speaking propranolol, Placebo - Social Anxiety Disorder | Phase 4 | Terminated | New York State Psychiatric Institute | 6 | 2016-06-01 | 2023-06-07 |
| Vortioxetine Versus Placebo in Major Depressive Disorder Comorbid With Social Anxiety Disorder Vortioxetine, Placebo - Social Anxiety Disorder, Major Depressive Disorder | Phase 4 | Unknown | The Medical Research Network | 40 | 2014-12-01 | 2016-08-24 |
| Treating Emotional Disorders in Primary Care With Psychological Techniques Cognitive Behavioral Treatment, Primary Care Treatment As Usual - Anxiety Disorders, Mood Disorders | Phase 4 | Completed | Psicofundación: Fundación Española para Promoción, Desarrollo Científico y Profesional de la Psicolo | 1126 | 2014-01-14 | 2020-03-10 |
| 12-Week Study of Pristiq (Desvenlafaxine) Social Anxiety Disorder Pristiq, Placebo - Social Anxiety Disorder | Phase 4 | Completed | The Medical Research Network | 63 | 2011-04-01 | 2016-10-17 |
| Escitalopram in Patients With Social Anxiety Disorder Escitalopram - Social Anxiety Disorder | Phase 4 | Completed | H. Lundbeck A/S | 30 | 2009-03-01 | 2011-06-10 |
| D-Cycloserine Enhancement of Exposure in Social Phobia Cognitive Behavioral Group Therapy (CBGT), D-Cycloserine, Placebo - Social Anxiety Disorder | Phase 4 | Completed | Massachusetts General Hospital | 169 | 2007-03-01 | 2014-05-14 |
| The Use of Quetiapine (Seroquel) in the Treatment of Social Phobia: Public Speaking Environment quetiapine - Social Phobia | Phase 4 | Completed | University of Minnesota | 20 | 2006-12-01 | 2011-10-27 |
| Primary Care Intervention Strategy for Anxiety Disorders Cognitive-behavioral therapy, Psychotropic medication optimization, Treatment as Usual - Post-traumatic Stress Disorder, Generalized Anxiety Disorder | Phase 4 | Completed | University of Washington | 1004 | 2006-06-01 | 2017-05-19 |
| Acamprosate in Alcoholics With Comorbid Anxiety or Depression Acamprosate - Alcohol Dependence, Major Depression | Phase 4 | Completed | Medical University of South Carolina | 90 | 2006-04-01 | 2015-04-13 |
| Adjunctive Quetiapine in the Treatment of Refractory Social Anxiety Disorder in Adults Quetiapine - Social Anxiety Disorder | Phase 4 | Completed | Cambridge Health Alliance | 40 | 2006-03-01 | 2017-04-18 |
| Improving Treatment Outcomes in Pharmacotherapy of Generalized Social Anxiety Disorder Sertraline, Venlafaxine, Placebo - Social Phobia | Phase 4 | Completed | Massachusetts General Hospital | 397 | 2006-03-01 | 2013-10-14 |
| Efficacy of Adding Topiramate to Current Treatment in Treatment-Resistant Generalized Social Phobia (GSP) Topiramate, Placebo - Social Phobia | Phase 4 | Terminated | McMaster University | 12 | 2004-03-01 | 2020-09-02 |
| Aripiprazole for the Treatment of Schizophrenia With Co-Morbid Social Anxiety Aripiprazole - Schizophrenia, Schizoaffective Disorder | Phase 4 | Completed | University of Medicine and Dentistry of New Jersey | 18 | 2004-03-01 | 2007-01-29 |
Showing 20 of 24. Sign in to see all of them.
Anxiety Disorders (9) · Generalized Anxiety Disorder (5) · Panic Disorder (5) · Depressive Disorder, Major (4) · Agoraphobia (3) · Alcoholism (2) · Dysthymic Disorder (2) · Attention Deficit Disorder with Hyperactivity (1) · Depression (1) · Mood Disorders (1) · Obsessive-Compulsive Disorder (1) · Phobia, Specific (1) · Psychological Well-Being (1) · Psychotic Disorders (1)
Mental Disorders (24) · Phobic Disorders (24) · Anxiety Disorders (15) · Depressive Disorder (4) · Mood Disorders (3) · Alcohol-Related Disorders (2) · Behavior (2) · Chemically-Induced Disorders (2) · Substance-Related Disorders (2) · Attention Deficit and Disruptive Behavior Disorders (1) · Behavioral Symptoms (1) · Neurodevelopmental Disorders (1) · Personal Satisfaction (1) · Schizophrenia Spectrum and Other Psychotic Disorders (1) · Trauma and Stressor Related Disorders (1)
Sertraline (3) · Antidepressive Agents (2) · Escitalopram (2) · Quetiapine Fumarate (2) · Acamprosate (1) · Acetaminophen (1) · Aripiprazole (1) · Benzodiazepines (1) · Botulinum Toxins, Type A (1) · Cannabidiol (1) · Clonazepam (1) · Cognitive Behavioral Therapy (1) · Cycloserine (1) · Desvenlafaxine Succinate (1) · Dexetimide (1)
The Medical Research Network (3) · Emory University (2) · Massachusetts General Hospital (2) · McMaster University (2) · Medical University of South Carolina (2) · Cambridge Health Alliance (1) · Daniel Lieberman (1) · Emine Kanmaz (1) · Georgetown University (1) · H. Lundbeck A/S (1) · Hamilton Health Sciences Corporation (1) · Jason Careri (1) · Massachusetts Institute of Technology (1) · New York State Psychiatric Institute (1) · Psicofundación: Fundación Española para Promoción, Desarrollo Científico y Profesional de la Psicolo (1)
United States (18) · Canada (4) · Russia (1) · Spain (1) · Turkey (Türkiye) (1)
Michael Van Ameringen, MD, FRCPC (4) · Murray B. Stein, MD, MPH (2) · Antonio R Cano-Vindel, Professor (1) · Carrie L Randall, PhD (1) · Cathy D. Sherbourne, PhD (1) · Charles B Nemeroff, MD, PhD (1) · Christopher B Donahue, Ph.D. (1) · Clinton D Kilts, PhD (1) · Daniel Z Lieberman, MD (1) · David E Adson, M.D. (1) · Franklin Schneier, MD (1) · Greer Sullivan, MD, MSPH (1) · Gustavo D Kinrys, MD (1)
PMID 19157776, PMID 19212970, PMID 19829198, PMID 20146834, PMID 20483968, PMID 21367351, PMID 21464362, PMID 21762829, PMID 22152230, PMID 22304968, PMID 22404963, PMID 23184657, PMID 23225338, PMID 23290323, PMID 23332608, PMID 23370069, PMID 23377641, PMID 23407203, PMID 23580378, PMID 23599046, PMID 23608160, PMID 23729989, PMID 23750465, PMID 23801589, PMID 23870811, PMID 23886736, PMID 24038728, PMID 24338947, PMID 24399428, PMID 24619599, PMID 24660674, PMID 25272965, PMID 25562579, PMID 26563229, PMID 27775823, PMID 36350591, PMID 39134156, PMID 39382900, PMID 40324655
R01AA013379 (1), R01MH070919 (1), R01MH075889 (1), U01MH057858 (1)